Title |
Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor
|
---|---|
Published in |
Journal of Translational Medicine, February 2014
|
DOI | 10.1186/1479-5876-12-41 |
Pubmed ID | |
Authors |
Jason K Sicklick, Stephanie Y Leonard, Michele L Babicky, Chih-Min Tang, Evangeline S Mose, Randall P French, Dawn V Jaquish, Carl K Hoh, Michael Peterson, Richard Schwab, Andrew M Lowy |
Abstract |
Gastrointestinal stromal tumor (GIST) is the most common sarcoma and its treatment with imatinib has served as the paradigm for developing targeted anti-cancer therapies. Despite this success, imatinib-resistance has emerged as a major problem and therefore, the clinical efficacy of other drugs has been investigated. Unfortunately, most clinical trials have failed to identify efficacious drugs despite promising in vitro data and pathological responses in subcutaneous xenografts. We hypothesized that it was feasible to develop orthotopic patient-derived xenografts (PDXs) from resected GIST that could recapitulate the genetic heterogeneity and biology of the human disease. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Malaysia | 1 | 2% |
Netherlands | 1 | 2% |
Canada | 1 | 2% |
Unknown | 40 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 16% |
Researcher | 6 | 14% |
Student > Ph. D. Student | 5 | 12% |
Other | 4 | 9% |
Unspecified | 3 | 7% |
Other | 8 | 19% |
Unknown | 10 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 35% |
Agricultural and Biological Sciences | 8 | 19% |
Unspecified | 3 | 7% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Veterinary Science and Veterinary Medicine | 1 | 2% |
Other | 2 | 5% |
Unknown | 12 | 28% |